Podcasts about pwh

A strong finish to a short week as the ASX 200 closed up 48 points to 7968 (0.6%). For the week we are up another 1.9%. A solid performance from the banks again with NAB up % and WBC rising %. The Big Bank Basket rose to $260.77 (+0.75%). MQG up another 1.2% as brokers upgraded post the Nomura deal. Fund managers picked up too, PNI up 2.6% and MFG rising 1.2%., GDG failed to touch the wall with its business update falling 14.9%. AMP feeling some love from brokers up 2.5%. ZIP also doing well as shorts covered. REITs better as an RBA rate cut beckons. At least according to WBC. Industrials relatively flat, tech better, WTC up 2.5% and the All-Tech Index up 0.6%. Healthcare saw gains with RMD doing well up 8.5% as it believes it is exempt from tariffs. The action again was in resources, BHP up 0.9% and FMG up 1.0%. Gold miners bounced back as bullion bounced and panic subsided. NEM quarterly helped and were up 3.5%, RRL up 4.1% with NST bouncing slightly. Shorts were being covered in uranium stocks again, PDN roaring ahead, up 12.1%, MIN up 5.9% and ILU up 2.4%. In corporate news, plenty of quarterlies dropping. PWH fell 5.7% as the CEO and founder is stepping back for medical leave. JHX is getting attention from Jim Chalmers on its move to redomicile without shareholder approval. On the economic front, WBC's economist Luci Ellis says a 25bps cut in May is now on the cards. Asian market mostly better. 10-year yields at 4.24%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Simon Miller interviews Paul Walter Hauser ahead of PROGRESS Las Vegas, where Miller's Proteus Title is on the line in a scramble match with PWH, Effy, Adam Priest, and Charles Crowley. Hauser talks paying dues, coming from acting to wrestling, David Arquette, giving back to the business, working for DEFY and MLW, Blackbird, picking his spots in wrestling and Hollywood, and more...ENJOY!Follow us on Twitter:@SimonMiller316@WhatCultureWWE Hosted on Acast. See acast.com/privacy for more information.

To kick off the new year, Marianna sits down with John Faragon to discuss new updates to the DHHS guidelines for people with HIV. Tune in to hear all about topics like transplantation for PWH, ART regimens, and more. -- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=PCS6722)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

You can text us here with any comments, questions, or thoughts!We're thrilled to bring you an enlightening conversation with Kemi and Deepika Slawek. Dr. Slawek is an Associate Professor of Medicine at Montefiore Health Systems and Albert Einstein College of Medicine in Bronx, NY in the Division of General Internal Medicine. She is board certified in Infectious Diseases, Addiction Medicine, and Internal Medicine and is the Co-Director of the Montefiore Medical Cannabis Program. Dr. Slawek studies how to reduce morbidity and mortality in people with HIV (PWH) and people who use drugs (PWUD) using a harm reduction framework. She aims to study solutions for PWH and PWUD informed by her clinical experiences and patient's experiences. Dr. Slawek is the recipient of a K23 award from the National Institute on Drug Abuse to test how different formulations of medical cannabis effect neuropathic pain and inflammation in PLWH in an innovative quasi-experimental study. She is leading groundbreaking foundation-funded research to determine whether medical cannabis is effective in reducing opioid analgesic use in people with pain and is an alumnus of our Get That Grant® coaching program! In this episode, Dr. Slawek shares her passion for HIV research, the social justice aspects of her work, the transformative power of coaching and: The value of carving out time for self-reflection and understanding the "why" behind your actions. How stopping to evaluate your work can be challenging but ultimately leads to more effective and meaningful use of your time. The importance of aligning your daily tasks with your broader values and goals. How regularly taking the time to assess your work and its impact can keep you grounded and prevent burnout, especially when the world feels overwhelming. Loved this convo? Please go find Dr. Slawek on Twitter/X and LinkedIn and show her some love!  And if you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.  REMINDER: Your Unapologetic Career Podcast now releases episode every other week! Can't wait that long? Be sure you are signed up for our newsletter (above) where there are NEW issues every month! 

In this episode, Tristan J. Barber, MA, MD, FRCP, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating PTSD in people with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, sharing their own experiences and approaches to thinking about PTSD, structuring appointments, and integrating care. Presenters:Tristan J. Barber, MA, MD, FRCPConsultant in HIV MedicineRoyal Free London NHS Foundation TrustHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonLondon, United KingdomGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides:https://bit.ly/4dBu929Program:https://bit.ly/3WB2VCO

In this episode, Bradley N. Gaynes, MD, MPH, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating depression in people living with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, including creation of a virtual network and employment of measurement-based care.Presenters:Bradley N. Gaynes, MD, MPHRay M. Hayworth, MD and Family Distinguished ProfessorProfessor of Psychiatry and EpidemiologyDirector, Division of Global Mental HealthCo-Director, Physician Scientist Training ProgramDepartment of PsychiatryUniversity of North Carolina School of MedicineChapel Hill, North CarolinaGlenn J. Treisman, MD, PhDEugene Meyer III Professor of Psychiatry and MedicineJohns Hopkins University School of MedicineBaltimore, MarylandDownloadable slides: https://bit.ly/3YgqqSOProgram: https://bit.ly/3WB2VCOTo get access to all of our new infectious disease podcast episodes, subscribe to the CCO infectious disease podcast channel on Apple Podcasts, Google Podcasts, or Spotify.  

This week, Marianna sits down with John Faragon to talk about vaccines and people with HIV. Learn about why it's important for PWH to stay up to date on their vaccinations, which vaccines specifically matter the most, and more.--Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=DFS6711)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

Dr. Ronald Collman, Director of the Penn Center for AIDS Research at the University of Pennsylvania, and Dr. Florence Momplaisir, Assistant Professor in the Division of Infectious Diseases and the Vice Chief for Diversity, Equity, and Inclusion, the Perelman School of Medicine at UPenn, discussed Philadelphia's rank as a national top 50 ‘hot spot' by the CDC for new HIV transmissions and their concerns for the city if Syringe Exchange Services are stopped.   After discussing the biology of HIV we looked at the numbers for our city, 20,000 persons with HIV in Philadelphia, 30,000 in region with almost 400 new infections per year.  While two-thirds of the people living with HIV are on treatment and suppressed, a third are not and are able to transmit the virus.  In Philadelphia 28% of the persons with HIV are women, one of the highest percentages in the country.  The primary transmission method is sex, however intravenous drug use is another cause, one that can soon explode with new city restrictions on needle exchange programming.  Treatments for HIV are great, but not as great as staying HIV negative: even with therapy, people with HIV are more likely to get the conditions of ageing including heart attacks, cancers, dementia and kidney failure.   Prevention is vital, if treated a person can reach U=U status, undetectable means un-transmittable.  PrEP, either daily oral or by scheduled injection, prevents infection, and there is even a ‘morning after' medication that can prevent the disease even through contaminated needle transmission.  Breaking down the numbers 64% of PWH are Black and 16% Hispanic.  The rates are 7x higher in Black & Hispanic and a Black male having sex with males faces a 1:3 lifetime risk for infection.  We discussed the underuse of treatment and PrEP in ethnic and minority communities, a combination of lack of knowledge and lack of access.  Youth numbers are also increasing, through carelessness and a mistaken belief that it is not a concern any more or that their circles are not affected. The two made their case for continued Syringe Exchange Services noting that when introduced to Philadelphia in the 90's, it reduced HIV transmission by 95%.  They pointed out that epidemics don't stay contained, and will penetrate the broader Philadelphia community, in particular women who will have acquired it through sexual contact.   They note that defunding clean syringes won't stop people from injecting, and syringe exchange is a major way that IDUs end up linked to rehab care successfully.    They also argued that saving $700,000 spent on needles will be more than offset by the cost for HIV and Hepatitis C care, as well as the cost of wound infections which is a huge burden on the City's health care system and a big user of ER services, which makes it harder for others to access ER services.   For more information about PrEp and other HIV services, contact the Philadelphia Department of Health at PhillyKeepOnLoving.com

We are BACK with another week on The POD as the boys have quite literally just gotten back from Philadelphia after experiencing what some are saying to be the greatest Wrestle Mania of all time! We get into all the adventures taken while out in the city and then soon jump right into the Pod FOD. The Pod FOD, which is a folder compiled of all things around the internet. This week's Pod FOD is jam packed, opening up with a list of English deaths in the year 1632, more airplane antics, PWH had his Mania moment, an update on Connor's favorite Lara team, and much much more. Make sure to subscribe to youtube.com/thepodpmi to watch full episodes and don't forget to send your submissions for the Pod FOD to @ThePodPMI on twitter and instagram. We appreciate you rocking with us and we'll see you Wednesday, Cheers.

We Are BACK with an almost full barn as the boys await the return of Lord Zito, they get right into the latest life events going on around the office. It is with a sad heart that Mitt gives out an RIP to The Toy after it has sadly been totaled. With the candid start from the boys, they wrap up movie talk and soon move onto the Pod FOD. The Pod FOD, which is a folder of all things compiled from the internet. Today's FOD includes this year's Emmy winners headlined by PWH himself, Tok's running attire, a man's “private” dinner party, Hulk Hogan being a superhero once again, and much much more. Make sure to subscribe to youtube.com/thepodpmi to watch full episodes and don't forget to send your submissions for the Pod FOD to @ThePodPMI on twitter and instagram. We appreciate you rocking with us and we'll see you Wednesday, Cheers.

This week, we're revisiting a conversation with John Faragon about NECA AETC's HIV mobile apps. From drug interactions to new guidelines, the apps cover it all. Learn all about some great features for HIV care providers and how you can use them daily to provide the best care for PWH.--Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=EWI5619)Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

This week, Marianna revisits a conversation with Dr. Jonathan Shuter, where they talk about an online course he developed in conjunction with the NECA AETC. Learn all about the course and sign up below. Sign-up for "Smoking Cessation in PWH": www.necaaetc.org/rise-courses Smoking cessation resources: National Smoking Quit Line: 1-800-QUIT-NOWwww.smokefree.govwww.becomeanex.org  --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=ROE5225)  Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. Check out our free online courses: www.necaaetc.org/rise-coursesDownload our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

This week we're chatting Sarah's time at GCW in STL, the return of Kairi and PWH and Ronda Rousey being booked at PW Revolver.

In this episode, Nikos Dedes, Jeff Taylor, and Bernadette Sharp—people living with HIV—discuss how switching to long-acting ART has affected their quality of life. They are joined by 2 healthcare professionals—Iskandar Azwa,MBChB, MRCP, and Beng Eu, MBBS—who provide insights on how they assess and document health-related quality of life for their patients. The discussion focuses on personal experiences with how LA ART has improved health-related quality of life, including:Avoidance of drug–drug interactionsImproved confidentiality Decreased stigmaPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://bit.ly/488WwT7Link to full program: bit.ly/3EwEnRJ

In this episode, Iskandar Azwa, MBChB, MRCP; Nikos Dedes; Beng Eu, MBBS; Bernadette Sharp; and Jeff Taylor discuss challenges and opportunities with long-acting ART implementation, including:Personal experiences with receiving LA ART Views on long-acting ART in the development pipelinePerspectives on self-administration of LA ARTPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic  Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://clinicaloptions.com/CE-CME/infectious-disease/slides-fourth-90-and-la-art/17553-25368  Link to full program: https://bit.ly/3EwEnRJ

This week, Marianna sits down with John Faragon to talk about a new treatment option for highly treatment experienced people with HIV. Tune in to learn more about a drug combination that HIV care providers have been looking at for this group of PWH. --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=CMP5323) 

This week, Marianna sits down with Dr. Jonathan Shuter to talk about a new (free!) online course he developed in conjunction with the NECA AETC. Learn all about the course and sign up below. Sign-up for "Smoking Cessation in PWH": www.necaaetc.org/rise-courses Smoking cessation resources: National Smoking Quit Line: 1-800-QUIT-NOWwww.smokefree.govwww.becomeanex.org  --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=ROE5225)  

This is Dice Tower Now for the week of June 20, 2023. This week, some call PWH a Space Cowboy, it's spelled M-O-N-O-P-O-L-Y, trick or treaters get DWARVEN GOLD, and Spain has one Paella to rule them all. And in the darkness bind them.   TOP STORIES (2:45) Spanish game store Gremio de Dragones offering $2M and a Paella for the One Ring MtG card Spellbook coming from Phil Walker Harding and Space Cowboys Quartermaster Direct bringing Last Resort by Oliver Brooks Alpaca from Christian Giove and Gate on Games Treasure of the Dwarves by Bruno Faidutti and Trick or Treat Studios Pythagoras Games announces Gods of Rome and Lata Ravensburger update on fixes coming to Puerto Rico 1897 Monopoly Scrabble. Yes, Monopoly Scrabble. Clue Conspiracy   CROWDFUNDING (13:10) Conquest Priness: Fashion is Power Sanssouci Kartini From Light to Darkness and Third Crusade Tiny Epic Boxes Stroganov Turukhan Monsters of Loch Lomond   SPONSOR UPDATE (23:30) Frosthaven Companion App   NEW RELEASES (25:30) Taelmoor by Eli Delventhal, Willem Delventhal and Zac Delventhal, self published by Delve Brothers Archaeos Society by Paolo Mori, published by Asmodee Hair of the Dog by Alexander Jerabek and Cherry Picked Games Seas of Strife by Mark Major and Rio Grande GAP by Rico Besteher and Frank Noack, published by Arcane Wonders Tiny Epic Vikings by Scott Almes and Gamelyn Games Books of Time by Filip Glowacz, published by Board and Dice Dorfromantik by Michael Palm and Lukas Zach, published by Pegasus Spiele Vaalbara by Olivier Cipiere and Studio H Stranger Things: Upside Down by Rob Daviau and Cool Mini or Not Inside Job by Tanner Simmons, published by Thames and Kosmos My City: Roll and Build by Reiner Knizia, published by Thames and Kosmos Tribes of the Wind by Joachim Thôme and Hachette     CONNECT: Follow our Twitter newsfeed: twitter.com/dicetowernow Dig in with Corey at DiceTowerDish.com. Have a look-see at Barry's wares at BrightBearLaser.com.

This week, Marianna sits down with John Faragon to talk about about the role of pharmacists when it comes to pre-exposure prophylaxis, or PrEP, and post-exposure prophylaxis, or PEP. Learn about how they can help PWH pay for PrEP & PEP, abandoned prescriptions, and more.  --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=YHN5046)  

In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines Data for weight gain after ART initiation with different ARV classes and drugsWeight gain disparities by race and gender after ART initiationData from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART The impact of INSTIs on CV events in the Swiss HIV Cohort study Recommendations for ART and contraception for PWH of childbearing potential Drug–drug interactions between first-line ART and contraceptive options Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH Marta Boffito, MD, PhD, FRCP Consultant Physician Clinical Director, HIV, Sexual and Gender Health, Dermatology Chelsea and Westminster Hospital NHS Foundation Trust Imperial College London London, United Kingdom Michelle Cespedes, MD, MS Professor of Medicine Division of Infectious Disease Department of Medicine Icahn School of Medicine at Mount Sinai New York, New York Link to full program: bit.ly/3HPu4Lk

In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:How HIV-ASSIST supports ART selection in primary careUpdates to viral hepatitis recommendations including:               CDC HBV screening and testing recommendations             AASLD simplified HCV treatment approach for PWHHIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction CheckerCarolyn Chu, MD, MSc, FAAFP, AAHIVSChief Clinical OfficerNational Clinician Consultation CenterProfessorClinical Family Community MedicineUniversity of California, San FranciscoSan Francisco, CaliforniaLink to full program: bit.ly/3pwaH2Y    

In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimensMaintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABCART regimen simplificationWhen to perform genotypic resistance testing, including for PWH who have been off ARTWhen to perform DNA genotyping for archived resistance testingConsidering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ARTUsing boosted DRV + DTG in salvage regimensSwitching from boosted PIs to INSTIs in PWH receiving second-line therapySecond-line regimens with LA CAB + RPV failure Christine Katlama, MD Professor Sorbonne University APHP Paris Head, HIV/Hepatitis Clinical and Research Unit Department of Infectious Diseases Paris, France Babafemi Taiwo, MBBS Gene Stollerman Professor of Medicine Chief, Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago, Illinois Link to full program: https://bit.ly/3Z44Gq3

In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:How to input patient specific factors into the HIV-ASSIST toolDiscussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancyAn explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequencyGuidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporatedHow to use the HIV-ASSIST output to guide regimen selection in pregnancyUse of the HIV-ASSIST tool in shared decision-making and patient counselingSonya Krishnan, MD, MHSAssistant ProfessorDivision of Infectious DiseasesJohns Hopkins UniversityBaltimore, MarylandLink to full program: bit.ly/3pwaH2Y

In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:Efficacy data with every-8-week dosingReal-world use in people with viremia Initiation and continuation strategiesVirologic failure dataSafety information Presenter:Ian Frank, MDAssociate ChiefDivision of Infectious DiseasesProfessor of MedicineUniversity of PennsylvaniaPhiladelphia, PennsylvaniaTo download the slides: https://bit.ly/3HX1GGn To view the full online program: https://bit.ly/3ZjSFhg 

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:Treatment in special populationsREDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumoniaRemdesivir and readmission for COVID-19 in immunocompromised patientsMolnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancyManagement of patients with severe diseaseRECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19Real-world study of tocilizumab vs baricitinib for severe COVID-19Novel antiviralsEnsitrelvirBemnifosbuvir Novel vaccinesNB2155AZD2816/AZD1222qNIV/CoV2373GRT-R910NVX-CoV2373 in people with HIVFaculty:  Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPIProfessor of Microbial DiseasesCentre for Experimental Pathogen Host ResearchUniversity College DublinDublin, IrelandContent based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  Link to full program: bit.ly/3niXGJ6Link to downloadable slides: bit.ly/3LUFejG

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:• Commonly implicated antiretroviral therapy regimens and patient populations• Guideline recommendations for management of weight gainPresenter:Daniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women's HospitalBoston, MassachusettsTo download the slides: bit.ly/3odUA9CTo view the full online program: bit.ly/3ZjSFhg

In this episode, Daniel R. Kuritzkes, MD, discusses considerations for rapid initiation of antiretroviral therapy in patients who are newly diagnosed with HIV, including:Recommended regimensManagement of patients previously receiving PrEPTiming of laboratory testingPresenter:Daniel R. Kuritzkes, MDHarriet Ryan Albee Professor of MedicineHarvard Medical SchoolChief, Division of Infectious DiseasesBrigham and Women's HospitalBoston, MassachusettsTo download the slides: https://bit.ly/3odUA9CTo view the full online program: https://bit.ly/3ZjSFhg

In this episode, Darcey Wooten, MD, discusses the long-acting HIV treatment agent lenacapavir for treatment-experienced people with HIV, including:Efficacy dataInitiation strategiesVirologic failure dataSafety informationPresenter:Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaTo download the slides:http://bit.ly/3Jb1ofXTo view the full online program:https://bit.ly/3ZjSFhg

 ASX 200 slipped 5 points to 7464 (0.1%) as an early rally reversed. The index does not tell the whole story though with huge volatility in some sectors. Some caution crept in ahead of the Fed and US results and end of month book squaring taking the wind out of the lithium sector and golds. Resources were smashed although BHP, RIO and FMG holding up but S32, IGO and PLS gave up the uneven struggle and threw in the towel short term, Quarterlies dropping all over the place. Gold miners failed to impress as NCM fell 1.2%, NST off 1.7% and EVN falling 2.4%. Rare earths too in the headlights, LYC down 3.3%, MIN off 3.9% and CXO falling 5.7% in lithium. Nasty end to the month from the resource sector. Oil and gas mixed, coal eased, NHC off 0.3%. Banks were flat with the Big Bank Basket unchanged yet again at $190.69. Insurers mixed and money managers eased, GQG off 4.4%. REITs slipped after some good sessions, GMG off 0.8% and CHC down 2.3%. Tech stumbled lower, CPU off 0.6% and XRO down 1.1%. The index dropped 1.0%. Healthcare recovered as defensives generally improved, CSL up 1.7% and RMD up 2.4% after a big drop yesterday. WOW flying on retail numbers up 3.8% and COL up 2.4%. In corporate news, it was all about quarterlies, MP1 were smashed 24.7% on a disappointing result, PBH in similar fashion as it extended its deal with NBC, down 17.4%. SYA dropped 11.9% on a successful ore crushing trial, PWH rallied hard up 5.0% on a UK acquisition and NXD starting to look interesting on an update, up 5.8%. FLT in a halt on a capital raise and UK acquistion. On the economic front, the December retail numbers missed by a country mile and showed that the Black Friday sales pulled spending out of Xmas. We got slightly better Chinese PMI numbers today. In Asia, Japan eased 0.2%, HK fell 1.2% and China off 0.8% after a huge run. 10-year yields at 3.52%. No great shakes post retail sales numbers. Why not sign up for a free trial? Get access to expert insights and research and become a better investor.

A new research paper was published in Aging (Aging-US) Volume 14, Issue 24, entitled, “Epigenetic aging is associated with aberrant neural oscillatory dynamics serving visuospatial processing in people with HIV.” Despite effective antiretroviral therapy, cognitive impairment and other aging-related comorbidities are more prevalent in people with HIV (PWH) than in the general population. Previous research examining DNA methylation has shown PWH exhibit accelerated biological aging. However, it is unclear how accelerated biological aging may affect neural oscillatory activity in virally suppressed PWH, and more broadly how such aberrant neural activity may impact neuropsychological performance. Participants (n = 134) between the ages of 23 – 72 years underwent a neuropsychological assessment, a blood draw to determine biological age via DNA methylation, and a visuospatial processing task during magnetoencephalography (MEG). Researchers Mikki Schantell, Brittany K. Taylor, Rachel K. Spooner, Pamela E. May, Jennifer O'Neill, Brenda M. Morsey, Tina Wang, Trey Ideker, Sara H. Bares, Howard S. Fox, and Tony W. Wilson from the Boys Town National Research Hospital, University of Nebraska Medical Center, Creighton University, Heinrich-Heine University, and the University of California San Diego focused their analyses on the relationship between biological age and oscillatory theta (4-8 Hz) and alpha (10 - 16 Hz) activity among PWH (n=65) and seronegative controls (n = 69). “To our knowledge, no study to date has directly linked accelerated biological aging in PWH to the neuro-functional changes that occur in cognitively impaired PWH, which include deficits in visuospatial processing, attention, working memory, and motor function networks.” PWH had significantly elevated biological age when controlling for chronological age relative to controls. Biological age was differentially associated with theta oscillations in the left posterior cingulate cortex (PCC) and with alpha oscillations in the right medial prefrontal cortex (mPFC) among PWH and seronegative controls. Stronger alpha oscillations in the mPFC were associated with lower CD4 nadir and lower current CD4 counts, suggesting such responses were compensatory. Participants who were on combination antiretroviral therapy for longer had weaker theta oscillations in the PCC. Full press release - https://www.aging-us.com/news_room/Aging-Epigenetic-aging-associated-with-aberrant-neural-oscillatory-dynamics-serving-visuospatial-processing-in-people-with-HIV DOI: https://doi.org/10.18632/aging.204437 Corresponding Author: Tony W. Wilson - tony.wilson@boystown.org Keywords: HIV, epigenetics, biological age, visuospatial discrimination, oscillations About Aging-US: Launched in 2009, Aging (Aging-US) publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Visit our website at www.Aging-US.com​​ and connect with us: SoundCloud – https://soundcloud.com/Aging-Us Facebook – https://www.facebook.com/AgingUS/ Twitter – https://twitter.com/AgingJrnl Instagram – https://www.instagram.com/agingjrnl/ YouTube – https://www.youtube.com/agingus​ LinkedIn – https://www.linkedin.com/company/aging/ For media inquiries, contact media@impactjournals.com.

In this episode, Monica Gandhi, MD, MPH, and Chloe Orkin, MBChB, FRCP, MD, discuss considerations for monkeypox, now called mpox, in people with HIV, including:The history of monkeypox (mpox)The current monkeypox (mpox) outbreakWhat we knew about monkeypox (mpox) in PWH prior to the current outbreakData in PWH from an international case series of monkeypox (mpox)CDC data regarding monkeypox (mpox) in PWHMonkeypox (mpox) treatment recommendationsDrug–drug interaction considerations between tecovirimat for monkeypox (mpox) and ARTMonkeypox (mpox) vaccination recommendations for PWHGlobal access to monkeypox (mpox) treatments and vaccinesWhether monkeypox (mpox) is a sexually transmitted infection and the implications of thatOngoing research on monkeypox (mpox) in PWHMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineUniversity of California, San FranciscoMedical DirectorWard 86 HIV ClinicSan Francisco General Hospital San Francisco, CaliforniaChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomLink to full program:https://bit.ly/3HPu4Lk

According to the Centers for Disease Control, pain is one of the most common reasons people seek medical care. However, for persons affected by hemophilia A and B, the experience of pain has provided the subtext for many issues related to health and wellbeing across the lifespan, and irrespective of gender, age, and, potentially, hemophilia severity levels. Although less-well characterized in children, pain is already embedded in the life experience of a PWH, and a substantial contributor to poor health-related quality of life in adolescence and young adulthood, further increasing in negative impact throughout adult life. In this episode, we explore pain's prevalence, mechanisms, and more.    Contributors: Nathalie Anne Roussel, PhD, MSc, PT Paul Mc Laughlin,  BSc, MSc, MMACP Michelle Rice    Senior Advisor: Donna DiMichele, MD   Episode Advisors (also contributors): Michelle Witkop, DNP, FNP-BC Tyler Buckner, MD   Hosted by: Patrick James Lynch   Show Notes: Presenting Sponsor: Sanofi Subscribe to the Global Hemophilia Report   Listen to BloodStream's Pain Podcast   Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter  

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​, discusses strategies for and importance of HIV care engagement and reengagement for those who have fallen out of care. Her overview includes:WHO Global Health Strategy on HIVLongitudinal HIV care trajectoriesPromotion of successful care and antiretroviral therapy (ART) adherenceDifferentiated service deliveryImproving care and ART adherence in high-risk groupsPatient perspectives on ART persistence Presenter:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​Director​Desmond Tutu HIV Centre​Past President​International AIDS Society​Faculty of Health Sciences​University of Cape TownCape Town, South Africa​Panelists:Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS-Infectious Diseases Medical Centre​DirectorChennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaChloe Orkin, MBChB, FRCP, MD​Professor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Babafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern University Feinberg School of Medicine​Chicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3dSNoumLink to full program:https://bit.ly/3AE2AV1

Andrew Wielandt from DP Wealth Advisory and Mark Gardner from Maqro Capital go in-depth and stock specific. Stocks covered: BHP, ANN, SYA, CPU, IXI, PWH, DXS, NXT BLD, VAS. Our stock of the day is James Hardie (JHX). Hosted on Acast. See acast.com/privacy for more information.

In this episode, listen to Priscilla Y. Hsue, MD, and Jens D. Lundgren MD, DMSc, discuss the latest data about ARV-related weight gain and cardiometabolic toxicities in PWH. Hear faculty:Review risk factors associated with significant weight gainConsider possible implications of weight gain and cardiometabolic toxicitiesShare their approaches to ARV-related weight gain and/or cardiometabolic toxicitiesFaculty:Priscilla Y. Hsue, MDProfessor of MedicineUniversity of California at San FranciscoSan Francisco General HospitalSan Francisco, CaliforniaJens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, DenmarkLink to full program:https://bit.ly/3PM3nYe

I'm so excited that you're here today because we are CELEBRATING! If you've been a long-time listener of the podcast, you know that one of my biggest goals and dreams in the entire world is to start a publishing house. And I'm so pumped to be able to tell you that... we did it. My friend & business partner, Kristina, and I successfully launched Power Within Her Publishing!!! There's a part of me that STILL cannot believe it, but it's true: I founded & co-own a publishing house!!!! To celebrate, I wanted to really take a second here with you and reflect on the path that led me here to this very moment. Because I think it's so cool to think about the path that got us to the other side of the big goal—no matter what that big goal is— because it's such a testimony of what's possible when you START! Thank you for being here with me!

In this episode, Babafemi Taiwo, MBBS, discusses strategies for reaching people with HIV who are not yet diagnosed. His overview includes:HIV diagnosis by global regionDisparities in serostatus awarenessPatient perspective on importance of HIV testingBarriers to HIV diagnosisComplications from late HIV diagnosisStrategies to improve rates of HIV testingPresenter:Babafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern UniversityFeinberg School of Medicine​Chicago, IllinoisPanelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDDirectorDesmond Tutu HIV Centre​Past PresidentInternational AIDS Society​Faculty of Health SciencesUniversity of Cape TownCape Town, South Africa​Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3PJRthDLink to full program:https://bit.ly/3AE2AV1

In this episode, Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, discusses the importance of linking people to care after a positive HIV diagnosis. His overview includes:HIV care continuumFactors that delay linkage to careOrganized strategies to improve linkage to care for people with HIVInterventions that may improve linkage to care for people with HIVPatient perspective on how to engage patients in their HIV care Presenter:Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaPanelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​Director​Desmond Tutu HIV Centre​Past President​International AIDS Society​Faculty of Health Sciences​University of Cape TownCape Town, South Africa​Chloe Orkin, MBChB, FRCP, MD​Professor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3PJ4iJ8Link to full program:https://bit.ly/3AE2AV1

In this episode, Chloe Orkin, MBChB, FRCP, MD​, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:Recommendations for rapid ARTFirst-line ART regimens for treatment-naive people with HIVIMEA 055 FAST studySTAT studyDIAMOND studyAntiretroviral resistance mutationsPatient perspectives on the importance of rapid ART initiationPresenter:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Panelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​DirectorDesmond Tutu HIV Centre​Past PresidentInternational AIDS Society​Faculty of Health SciencesUniversity of Cape TownCape Town, South Africa​Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaBabafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern UniversityFeinberg School of Medicine​Chicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3dSNoumLink to full program:https://bit.ly/3AE2AV1

Scott Phillips from The Motley Fool and Mark Moreland from Teaminvest go in-depth and stock specific. Stocks covered: HUB, PMV, TYR, LYC, RWC, NSR, ABY, PWH, SGR, BOQ. Our stock of the day is Scentre Group (SCG). Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

In this episode, Yvette Raphael provides her perspectives and advice as an individual living with HIV in South Africa for more than 20 years. She shares her experiences and ideas for how to improve processes related to HIV diagnosis, care linkage, and treatment.Presenter:Yvette RaphaelContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/3tmgozy

Adam Dawes from Shaw and Partners and Mathan Somasundaram from Deep Data Analytics go in-depth and stock specific. Stocks covered: PWH, BLD, ALU, BHP, MNS, BBN, DRO, TCL, YMAX, PGL . Our stock of the day is Healius (HLS). See acast.com/privacy for privacy and opt-out information.

India Policy Watch: Why is UBI Back Again?Insights on burning policy issues in India- Pranay KotasthaneThe Universal Basic Income (UBI) proposal made it to last week's policy headlines. The occasion was the release of a report commissioned by the Economic Advisory Council to the Prime Minister. Written by the Institute for Competitiveness, the State of Inequality in India Report bats for “raising minimum income and introducing universal basic income” to reduce “the income gap and equal distribution of earnings in the labour market”. There is no cost-benefit analysis or implementation details of the UBI in the report. Nevertheless, since this report has been commissioned by a government advisory body just a couple of years ahead of the next national election, the report has rekindled the conversation on UBI.What Do We Know About the UBI in India?UBI has been extensively discussed ever since the Economic Survey 2016-17. It is one of those rare ideas for which you will find liberal and progressive arguments both for and against it. So I’ll skip the usual arguments and get to the crux of the UBI in India. What we know is that a “Universal. Basic. Income.” is an impossible trinity in the Indian context. The government can at best meet two but not all three of its elements—a basic income that won’t be universal; a universal income that will be way below what qualifies as “basic”; or something that is universal and basic but not in the form of an income. This trilemma arises due to two reasons. One, India is just not rich enough for the government to fund a full UBI by taxing citizens at reasonable rates. The Economic Survey estimated that even a non-universal basic income for 75% of Indians would cost nearly 5% of the GDP. For context, the total expenditure incurred by the union government including all its portfolios was approximately 13% of GDP before the pandemic. Two, some proponents of UBI argue that the government can stop existing implicit and explicit subsidies, and use the savings to fund a UBI. The UBI would eliminate leakages, obviate the need for complex delivery machinery, and reduce incentives for corruption, they explain. But in a democratic setup where every political party finds it imperative to give individual handouts before elections, this is a leap of faith. It’s more likely that taxpayers will foot the bill for all current subsidies in addition to the UBI.Realising this trilemma, political proposals after the Economic Survey report have tended towards the first option— a targeted basic income scheme, which is non-universal by definition. One such formulation, the Minimum Income Guarantee Scheme for the Poor (MIGS), made it to the Indian National Congress’ 2019 manifesto. What Explains the UBI’s Return to the Headlines?This conversation on variants of UBI has picked up the pace again. Like any major crisis, the pandemic has impacted the poor more than the rich. And hence, various income support schemes are back in favour. The Overton Window seems to be shifting. Interestingly, this trajectory towards increased monetary transfers after a major crisis was anticipated in a book nearly 60 years ago. In a 1961 book titled The Growth of Public Expenditure in the United Kingdom, economists Alan Peacock and Jack Wiseman observed the patterns of government spending in the UK between 1890-1955. The dominant view at that time was that government spending as a proportion of the overall economy keeps rising organically as citizen demands grow with rising incomes. In a poor country, most citizens make do with the State providing them with the bare basic public services. But as incomes and government revenues rise, citizens demand that the State also provide them with quality education, low-cost healthcare, and affordable housing, and so on.Peacock and Wiseman challenged this view of the organic growth of government spending. They saw that government spending rise in the UK happened in the form of step-jumps due to major crises (and there were many in their study period). Their explanation of this phenomenon was as follows. In normal times, the level of public spending is capped by the acceptable level of taxation. Even if citizens might find a higher level of government spending desirable, they won’t accept a higher rate of taxation in return. This equilibrium is shattered by a crisis such as a war, where government spending and rates of taxes increase to manage the immediate difficult situation at hand. However, once the crisis recedes, new ideas of tolerable taxation levels emerge, and government spending does not go back to its original position. This conjecture came to be known as the Peacock-Wiseman Hypothesis (PWH).Are we seeing PWH in action in India, because of COVID-19? If one were to look at costly expenditure policies such as UBI, speculations about a GST rate of 8% replacing the 5% rate, and the high fuel taxes, it does seem that we are moving towards a new normal in government spending. Another interesting element of this hypothesis is the “inspection” effect:“social upheavals impose new and continuing obligations on governments both as the aftermath of functions assumed in wartime (e.g., payments of war pensions, debt interest, reparation payments) and as the result of changes in social ideas. Wars often force the attention of governments and peoples to problems of which they were formerly less conscious—there is an "inspection effect," which should not be underestimated.”The optimist would say that the inspection effect might lead Indian governments to finally focus on key areas such as pro-market reforms, liberalisation of factor markets, defence, poverty reduction and public health. But the realist would argue that the policy debate on public health hasn’t matured enough to present viable options, and hence it is more likely that the government might opt to spend on “quick-win” schemes such as the UBI or PLI, which are simpler and intuitive at face value. So, on the whole, we should keep a close eye on the government spending trajectory.PS: Peacock and Wiseman hasten to remind us that their conjecture is not inevitable, the reality depends on the social and economic context of the crisis itself. Speaking about PWH, we’re hosting a conversation with India’s foremost authority (and my public finance teacher), Dr Govinda Rao, this Friday. His latest book Studies in Indian Public Finance narrates India’s tryst with taxes, debt, expenditures and budgets. A must-read for any public policy enthusiast.Global Policy Watch #1: Axel Leijonhufvud On His Tribe  Global policy issues relevant to India - RSJ“The Econ tribe occupies a vast territory in the far North. Their land appears bleak and dismal to the outsider and travelling through it makes for rough sledding; but the Econ, through a long period of adaptation, have learned to wrest a living of sorts from it. They are not without some genuine and sometimes even fierce attachment to their ancestral grounds, and their young are brought up to feel contempt for the softer living in the warmer lands of their neighbours such as the Polscis (Political Scientists) and the Sociogs (Sociologists). Despite a common genetical heritage, relations with these tribes are strained-the distrust and contempt that the average Econ feels for these neighbours being heartily reciprocated by the latter-and social intercourse with them is inhibited by numerous taboos. The extreme clannishness, not to say xenophobia, of the Econ makes life among them difficult and perhaps even somewhat dangerous for the outsider. This probably accounts for the fact that the Econ have so far-not been systematically studied. Information about their social structure and ways of life is fragmentary and not well validated. More research on this interesting tribe is badly needed.”That’s how the paper ‘Life Among The Econ’ began in the September 1973 edition of Western Economic Journal. Written by a young professor at UCLA, Axel Leijonhufvud, the paper was a humorous take on economists as a tribe written in the style of a field paper of an anthropologist. Reading it almost fifty years after it was written, it is hilariously accurate and relevant.Axel Leijonhufvud died earlier this month. His defining work was his 1968 book ‘On Keynesian Economics and the Economics of Keynes’ where he questioned the validity of the IS-LM model that had become the foundation for applying Keynesian economics. The success of Keynesian economics and the subsequent research on it had made most believe that there was nothing left anymore to discover in macroeconomics. Leijonhufvud proposed a radical departure from this consensus. He called it the ‘cybernetic’ approach that begins with rejecting the notion that the system is in a state of equilibrium. Instead, he argued that the economy is always in a dynamic state which is continually evolving based on initial information available with transactors - their endowments, beliefs, expectations, existing relationships, assets etc. There are a set of possible actions given an initial state and the behavioural rules that will dictate what next step will be chosen. Economic systems, he claimed, operate at a tactical, transaction level with no planned long-term goal. You can study this over time and there will be patterns of behaviour and reference points that will emerge based on the initial set of assumptions but there’s no guarantee things will always converge to an equilibrium. It was an intellectual challenge to Keynesian consensus and laid the ground for the takeover of the field by the adherents of the rational expectations theory. Famously, his book that theorised at length on macroeconomics didn’t have a single formula. He didn’t need them to make his point. Leijonhufvud believed then (1971) that economics was being taken over by top-down quant models without having an ear to the ground. 50 years later you could argue things have gotten worse.Anyway, I will leave you with a sample of Leijonhufvud’s dry wit from his anthropological study of the econ tribe.On status among economists:“A comparison of status relationships in the different “fields” shows a definite common pattern. The dominant feature, which makes status relations among the Econ of unique interest to the serious student, is the way that status is tied to the manufacture of certain types of implements, called “modls.” The status of the adult male is determined by his skill at making the “modl” of his “field.” The facts (a) that the Econ are highly status-motivated, (b) that status is only to be achieved by making ”modls,” and (c) that most of these “modls” seem to be of little or no practical use, probably accounts for the backwardness and abject cultural poverty of the tribe. Both the tight linkage between status in the tribe and modlmaking and the trend toward making modls more for ceremonial than for practical purposes appear, moreover, to be fairly recent developments, something which has led many observers to express pessimism for the viability of the Econ culture.”On the primacy of models over everything else:“While in origin the word “modl” is simply a term for a concrete implement, looking at it only in these terms will blind the student to key aspects of Econ social structure. “Modl” has evolved into an abstract concept which dominates the Econ’s perception of virtually all social relationships-whether these be relations to other tribes, to other castes, or status relations within his caste. Thus, in explaining to a stranger, for example, why he holds the Sociogs or the Polscis in such low regard, the Econ will say that “they do not make modls” and leave it at that. The dominant role of “modl” is perhaps best illustrated by the (unfortunately very incomplete) accounts we have of relationships between the two largest of the Econ castes, the “Micro” and the “Macro.” Each caste has a basic modl of simple pattern and the modls made by individual members will be variations on the theme set by the basic modl of the caste. Again, one finds that the Econ define the social relationship, in this instance between two castes, in terms of the respective modl. Thus if a Micro-Econ is asked why the Micro do not intermarry with the Macro, he will answer: “They make a different modl,” or “They do not know the Micro modl.” (In this, moreover, he would be perfectly correct, but then neither, of course, would he know the Macro modl.)”On the future of Economics:It would be to fail in one’s responsibility to the Econ people to end this brief sketch of life in their society without a few words about their future. The prospect for the Econ is bleak. Their social structure and culture should be studied now before it is gone forever. Even a superficial account of their immediate and most pressing problems reads like a veritable catalogue of the woes of primitive peoples in the present day and age. They are poor-except for a tiny minority. miserably poor. Their population growth rate is among the highest in the world. Their land is fairly rich, but much of the natural resources that are their birth-right has been sold off to foreign interests for little more than a mess of pottage. Many of their young are turning to pot and message. In their poverty, they are not even saved from the problems of richer nations-travellers tell of villages half-buried in the refuse of unchecked modl-making and of the eye-sores left on the once pastoral landscape by the random strip-mining of the O’Metrs. It is said that even their famous Well Springs of Inspiration are now polluted. In the midst of their troubles, the Econ remain as of old a proud and warlike race. But they seem entirely incapable of “creative response” to their problems. It is plain to see what is in store for them if they do not receive outside aid.Global Policy Watch #2: Let Musk Play  Global policy issues relevant to India - RSJElon Musk couldn’t have existed at any other time in human history. Because at no other point in our history would it have been possible to simultaneously be the richest person in the world, run the most innovative and bold business enterprises, troll powerful politicians and colleagues, show a fine disregard for the law (esp SEC’s laws), smoke a joint on live web TV, create asset bubbles with just a single word and also be seen by millions as a messiah. A thousand years from today just studying the life and times of Elon Musk would be enough to understand the 21st century. And this would have been true even a couple of months ago. However, that’s not enough for Musk. In the last few weeks, he has gone further. In April, he made a bid for buying out Twitter, the platform that is seen as the global public square of our times and taking it private. Of course, he bid for it at $54.20 per share because he cannot resist a ‘420 marijuana joke’ when he takes these important decisions. And since then, he’s been trolling Twitter. On Twitter. About its management, the likely bots it has as users, its policy on censoring content, its product features and on how its headquarters might be better used a shelter for the homeless. While it is tremendous entertainment for onlookers, there are those who are worried about the implications of a very rich man with strong libertarian and, often strange right-wing beliefs owning the most influential social media platform in the world. Twitter is already chaotic with bad actors manipulating the platform to trend topics, troll people and create a fake news industry that has ruined lives, influencing elections and creating just about the worst kinds of influencers in countries around the world. The initial euphoria of it providing a voice to ordinary citizens, getting rid of the gatekeepers and the hope of many more Arab Springs have been replaced by a cynicism that it is a platform that can be abused by those with more resources for their political ends. And into this chaotic world, now we will have the king of chaos, Musk, himself holding the reins. This could get really bad.Or will it?At the heart of this issue is that old question that Plato tried to answer in ancient Greece. Who should hold power in a society and how should the use of that power be regulated?There are three key concerns I read about Musk owning Twitter and it is useful to understand them a bit more.First, there are problems with Twitter today. Bots, fake news, concerted abuse by mobs and somewhat random ways of censoring voices. These issues aren’t helped by its lack of transparency – the algorithm it uses to recommend and trend topics or how it decides on clamping down on certain accounts or tweets are all shrouded in mystery. People abuse the platform for their benefit while Twitter often ends up punishing the wrong guy. Musk has zeroed in on the source of this problem. To him, the platform is optimising for the attention of the user and its algorithms are built to reinforce your biases over and over again. And no one outside of Twitter knows how the algorithm decides which biases will it reinforce and which it won’t. Over time, he fears this lack of transparency will erode trust among users and reduce the effectiveness of the algorithm because of a lack of credible challenge from the outside. He views this as an engineering problem and to quote him – “open source is the way to go” – to solve this. That sounds vague but, hey, it is Musk talking. You can trust him to find the technical solution to this.Those who oppose Musk buying Twitter are worried that this ‘engineering tech-bro’ mindset has gotten us into this mess in the first place. Musk might be good at putting rockets in space and, possibly, colonising Mars someday but solving a complex social problem is a different ball game. It requires a deeper understanding of people, their motivations and a mind that can think beyond rational expectations and incentives. Giving Musk the charge to make Twitter better is the equivalent of handing the keys of the asylum over to its inmates. That’s the argument. I’m less than convinced about this. Twitter is a technology platform. Its engagement with its users, its feature of bringing the latest information to your feed and its ability to create a network for you based on how you use it are all products of its technology. The choices it has made on technology have created it in the shape it is today which is different from say, Facebook or Reddit. If the platform encourages click-baits, reinforces biases and tribal loyalties through the like button and optimises for your attention, the solution to it cannot be to solve for human nature. That is an unsolvable problem. This is an engineering problem. Sure, as history has shown once you think you have solved it, the problem will shift. This is an ongoing process in science and every technological innovation has evolved in this way over the centuries. The solution to human mobility has over time gone from horses to cycles to cars to aircraft with each solution bringing with it newer problems. Nobody has ever contended that the real solution is for humans to develop wings.Two, there is a view that platforms like Twitter are a public good and it shouldn’t be owned by rich, powerful people like Musk. I can grudgingly admit that Twitter is like a public good. But that only means there’s a need for the state to intervene in framing guidelines on how it will be used. It doesn’t necessarily follow that it should be owned by the state. That would be a catastrophic mistake. There’s a long history of media being owned by the rich around the world. The state in most democracies has understood the criticality of media in the scheme of things and managed it well so far. Media moguls have influence but none has ever become a law unto themselves. On the other hand, the state has tried but it has not managed to stifle free speech. We have been worried about this equilibrium for a long time. As far back as 1941, Hollywood was making Citizen Kane about a powerful media owner and his outsized influence on politics and society. Media has only diversified and thrived since. Musk might suffer from a God complex. He might want to be the techno-feudal overlord of the universe. Even if he were to become one, he will still be less powerful than the state.  Three, there is a belief that Musk is a canny operator and perhaps someone who understands the power of Twitter more than anyone else in this world. His reason for owning the platform is to have a free run to do things he likes to do in his spare time – troll the SEC, progressive left and other adversaries in business; pump up meme stocks or dodgy cryptocurrencies, make gains at the expense of his stupid followers and, who knows, probably build a base for some kind of a career in politics. So, Twitter is an expensive toy that he loves. He will play with it till he gets bored. At the end of it, the world will be poorer for his misadventure because Twitter is still an amazing platform for good.Should he be allowed to run a platform like Twitter to the ground because he has the money and the power? Well, maybe not. But the truth is that he has the power and the money because he has been proven right many times over. There is no divine reason for his magic. He commands trust among his millions of followers because he makes the seemingly impossible possible. Were he to take advantage of that trust to the detriment of his followers, he will begin to lose that power. Musk takes long-range bets – electric vehicles, space travel, EV batteries, hyperloop – and his credibility is the only reason why investors trust him to pull these off. He should know the perils of short-term gains at the expense of that credibility. He will not take a punt on that.There are market failures that need attention in big tech and social media businesses. Elon Musk buying Twitter won’t make this worse. These failures need policy interventions that regulate the market dominance and the information advantage these companies have. Those are the guardrails that the state and the regulators need to build. The Musk Twitter drama is a sideshow.  HomeWorkRecommended podcasts, papers, and articles on public policy matters [Paper] Mihir Mahajan and Shekhar Sathe estimate additional deaths in the pandemic years by using publicly available insurance data. TL;DR - the estimates are quite close to the WHO-reported numbers. If you prefer a podcast on this topic, listen to our Puliyabaazi.[Paper] This old paper asks: Did India’s public expenditure follow the Peacock-Wiseman Hypothesis as a result of the 1962 India-China War? TL;DR - yes, partially.[Article] Over at New Things Under the Sun, Matt Clancy summarises the literature that investigates the relationship between population and innovation. The evidence suggests that bigger populations are generally better for innovation.[Podcast] This BIC Talks episode with Faisal Devji on Gandhi is top-notch. [Paper] For a libertarian critique of the UBI, read Bryan Caplan. “The UBI is a triumph of simplicity over numeracy”, he says. Of course, he is speaking from the American socio-political context. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit publicpolicy.substack.com

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).Listen as she gives perspectives on:Department of Health and Human Services (DHHS) guideline recommendations for transgender PWHProviding HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitatorsGender-affirmative hormone therapy optionsDrug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapyRecommended laboratory monitoring while receiving gender-affirming hormone therapyThe cascade of care for transgender PWH and barriers to engagement and retention in carePresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV  Children's Hospital at MontefiorePediatric Hospital of Albert Einstein  College of MedicineBronx, New York  Follow along with the slides at:https://bit.ly/3wOdKVoLink to full program:https://bit.ly/3fOl0XX

Rudi Filapek-Vandyck from FN Arena and Henry Jennings from Marcus Today go in-depth and stock specific. Stocks covered: PNV, PWH, AVG, AQZ, OBL, VCX, SWF, HT1, QBE, AX1. Our stocks of the day are ETFS Physical Gold (GOLD) and Macquarie (MQG). See acast.com/privacy for privacy and opt-out information.

Decision Space is the podcast about decisions in board games! Click on the link to join our active and welcoming Discord community!  Join the crew today! (Decision Space Patreon)   Episode 65 - Sushi Go! Sushi Go! by Phil Walker-Harding is our feature game in this week's episode. As card-carrying members of the PWH fan club, we're excited to sink our teeth into this super-light game. We'll explore the decisions in the game and offer card-by-card analysis. If that wasn't enough, it is also the return of the "What's on My Mind" segment, where Jake shares his recent entanglement with Azul Queen's Garden. It's a good one, hop in the Interdecisional Spaceship and enjoy!   Games Discussed Sushi Go! and Azul Queen's Garden   Timestamps Intro - 0:00 Azul Queen's Garden - 2:37 Sushi Go! - 10:30 Rules Overview - 15:26 Feature Discussion - 16:43   Music Credits Thank you to Hembree for our intro and outro music from their song Reach Out. You can listen to the full song on YouTube here: https://www.youtube.com/watch?v=gQuuRPfOyMw&list=TLGGFNH7VEDPgwgyNTA4MjAyMQ&t=3s You can find more information about Hembree at https://www.hembreemusic.com/.  Rules Overview Music:  Way Home by Tokyo Music Walker https://soundcloud.com/user-356546060​ Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/tokyo-music-walker-way...​ Music promoted by Audio Library https://youtu.be/pJThZlOuDtI   Contact We can be reached individually on Twitter at @jakefryd and @burnsidebh. You can also follow Decision Space on Twitter @DecisionSpa and talk to us there! If you prefer email, then hit us up at decisionspa@gmail.com. This information is all available along with episodes at our new website decisionspacepodcast.com. Bye!  

NDC sits down with PWH founders and visionaries, Dr. Anne Eiting Klamar, Midmark's Chair of the Board, and Cindy Juhas, CME's Chief Strategy Officer, to discuss the need, benefits and importance of diversity in leadership. Since its inception, Professional Women in Healthcare (PWH) has empowered women to lead and succeed – and nearly two decades later – continues to build towards a culturally inclusive healthcare industry equally led by women. In this podcast, we discuss the journey and inflection points of the PWH organization and how the mission has evolved to include integrated leadership development for the entire industry.

In this episode, Jürgen K. Rockstroh, MD, discusses his recommended approach for diagnosing nonalcoholic steatohepatitis in patients with HIV, the value of noninvasive diagnostic tests such as serum biomarkers and elastography, and how timely nonalcoholic fatty liver disease assessment and metabolic risk factor determination can result in early interventions.Presenter:Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program:https://bit.ly/3Gk7juJ

In this episode, Rageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIV, and Solange L. Baptiste, ScM, discuss the burden of HIV among BIPOC and migrant communities and key strategies to reduce racial disparities in HIV care globally:Disproportionate impact of HIV among BIPOC communities and migrant populations globallyBarriers to HIV testing, prevention, and treatment services among BIPOC communities and migrant populationsStrategies to overcome health system–based and provider-based barriers to engagement with HIV careRageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIVHonorary Senior Lecturer in HIV MedicineBlizard Institute, Faculty of Medicine and DentistryQueen Mary University of LondonConsultant Physician in HIV MedicineDepartment of Infection and ImmunityBarts Health NHS TrustLondon, United KingdomSolange L. Baptiste, ScMExecutive DirectorInternational Treatment Preparedness CoalitionBryanston, South AfricaContent based on a CME program supported by educational grants from AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP  To follow along, download the slides at:https://bit.ly/3ngDrsvLink to full program:https://bit.ly/3gh6WXj

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:DHHS, EACS, IAS, and WHO recommendations for first-line ARTVirologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National SurveyPolypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairmentCardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ARTPresenters:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal Medicine  Chair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, Florida  Jens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenCopenhagen, DenmarkDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, Denmark  Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3miT6qHSee the entire program at: https://bit.ly/2TXTYWx 

In this episode, Martin C. Mahoney, MD, PhD, discusses new data on vaccine-preventable diseases from IDWeek 2021, including:Pneumococcal diseaseRespiratory syncytial virus (RSV)Herpes zosterInfluenzaPresenter:Martin C. Mahoney, MD, PhD  Professor of OncologyDepartment of Internal MedicineRoswell Park Comprehensive    Cancer InstituteBuffalo, New York  Follow along with an expanded slideset at:https://bit.ly/3Ev8ozrLink to full program:https://bit.ly/3BCHF2E

Michael Wayne from Medallion Financial and Andrew Page from Strawman go in-depth and stock specific. Stocks covered: RZI, EGR, NDQ, JDO, HUB, SHJ, HVST, DUB, MQG, PWH. Our stock of the day is Pushpay (PPH).Watch the full episode here:https://ausbiz.co/Call See acast.com/privacy for privacy and opt-out information.

In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:Metabolic factors  HIV-related factorsWhich patients with HIV are at riskPresenter:Giada Sebastiani, MDAssociate Professor of MedicineMcGill University Health CentreDivision of Gastroenterology and Hepatology and Division of Infectious DiseasesClinician ScientistResearch Institute of McGill University Health CentreMontreal, Quebec, CanadaContent based on an online CME program supported by an educational grant from Theratechnologies Inc.Link to full program: https://bit.ly/3BYoXBP

Rudi Filapek-Vandyck from FNArena and Claude Walker from A Rich Life go in-depth and stock specific. Stocks covered: PWH, CGS, ERD, JHX, STG, 4DS, RHC, OCL, NWL, RMD. For our future fund stock series, Rudi and Claude picked IDP Education (ASX:IEL) and Alphabet (NYSE:GOOGL) respectively. See acast.com/privacy for privacy and opt-out information.

With the volume of music released each week, some is bound to not get the attention it deserves. This week hosts Jim DeRogatis and Greg Kot share some of their recent finds and shine a light on them. They also talk with Israeli musician Tamar Aphek about her album "All Bets Are Off." Join our Facebook Group: https://bit.ly/3sivr9TBecome a member on Patreon: https://bit.ly/3slWZvcSign up for our newsletter: https://bit.ly/3eEvRnGMake a donation via PayPal: https://bit.ly/3dmt9lURecord a Voice Memo: https://bit.ly/2RyD5Ah Featured Songs:Tamar Aphek, "Crossbow," All Bets Are Off, Kill Rock Stars, 2021Mushroom, "Two Men Say They're Jesus, One of Them Must Be Wrong," Songs of Dissent: Live at the Make Out Room 8/9/19, Alchemikal Artz, 2021U.V.T.V., "Back To Nowhere," Always Something, Papercup Music, 2021Shower Curtain, "You Make Me Feel," You Make Me Feel (Single), Balaclava , 2021Ka, "PWH," A Martyr's Reward, Iron Works, 2021Pist Idiots, "Juliette," Idiocracy, PIST IDIOTS, 2021HotKid, "Letter," Letter (Single), Fortune Stellar, 2021The Armed, "Ultrapop," Ultrapop, Kill Rock Stars, 2021Tamar Aphek, "Show Me Your Pretty Side," All Bets Are Off, Kill Rock Stars, 2021Tamar Aphek, "Drive," All Bets Are Off, Kill Rock Stars, 2021Tamar Aphek, "Russian Winter," All Bets Are Off, Kill Rock Stars, 2021Tamar Aphek, "Nothing Can Surprise Me," All Bets Are Off, Kill Rock Stars, 2021Tamar Aphek, "Beautiful Confusion," All Bets Are Off, Kill Rock Stars, 2021Monotonix, "Body Language," Body Language, Drag City, 2008Tamar Aphek, "All I Know," All Bets Are Off, Kill Rock Stars, 2021Tamar Aphek, "As Time Goes By," All Bets Are Off, Kill Rock Stars, 2021Kacey Musgraves, "justified," star-crossed, Interscope/UMG Nashville, 2021

In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.  This episode includes discussion of:An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWHCALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWHA Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patientsA Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEPZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TBPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases  Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/3hvRN5bContent based on an online CME program supported by an educational grant from ViiV Healthcare.

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.  This episode includes discussion of:A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimensA Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimenPresenters:Eric S. Daar, MDChief, Division of HIV MedicineHarbor-UCLA Medical CenterProfessor of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaShobha Swaminathan, MDAssociate ProfessorDivision of Infectious Diseases  Department of MedicineRutgers New Jersey Medical SchoolNewark, New JerseyFollow along with the slides at:https://bit.ly/2WZu7zmContent based on an online CME program supported by an educational grant from ViiV Healthcare.

Rudi Filapek-Vandyck from FNArena and Claude Walker from A Rich Life go in-depth and stock specific. Stcosk covered: PME, BKG, DTC, PWH, EOL, PNI, PLY, RZI, BXB, EML. Our stock of the day is TechnologyOne (TNE). See acast.com/privacy for privacy and opt-out information.

In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year periodThe DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosisA rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse eventsThe ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPVSWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effectiveGEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDFTANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimenIn addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms.  Presenter:Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women's HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsFollow along with the slides at:https://bit.ly/3zdPwm2 Content based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8

Listen to expert insights from Joseph J. Eron, Jr., MD, on exciting data about investigational agents (dapivirine ring, islatravir, lenacapavir, broadly neutralizing antibodies) for next-generation HIV prevention.Joseph J. Eron, Jr., MDProfessor of Medicine and EpidemiologyUniversity of North Carolina School of MedicineDirector, AIDS Clinical Trials UnitUniversity of North CarolinaChapel Hill, North CarolinaLink to full program:https://bit.ly/3ux6FF8

Listen to expert insights from W. David Hardy, MD, on current options for pre-exposure prophylaxis and exciting new data on next-generation HIV prevention.W. David Hardy, MDScientific and Medical ConsultantAdjunct Clinical Professor of MedicineDivision of Infectious DiseasesKeck School of Medicine of USCLos Angeles, CaliforniaContent based on a CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8

Mathan Somasundaram from Deep Data Analytics and Gaurav Sodhi from Intelligent Investor go in-depth and stock-specific. Stocks: ILU, WOR, ALU, MYQ, ASX, PWH, SXE, WOW, GLB, TYR. Stock of the day is Super Retail Group (SUL). See acast.com/privacy for privacy and opt-out information.

Jun Bei Liu from Tribeca Investment Partners and Adam Dawes from Shaw and Partners go in-depth and stock-specific. Stocks: TCL, BRN, SKO, MFG, PWH, JHG, JHX, IAG, BAP, MVF. The stock of the day is Frontier Digital Ventures (FDV). See acast.com/privacy for privacy and opt-out information.

Julia Lee from Burman Invest and Michael Gable from Fairmont Equities go in-depth and stock-specific. Stocks: TYR, SXL, HYD, PWH, ALU, MND, INF, WOA, PWN, ETHI. The stock of the day is A2 Milk (A2M). See acast.com/privacy for privacy and opt-out information.

Kris and Socbs from PWH come on to talk about the previous season hunting coyotes in southern Saskatchewan.  We also dive into the benefits of the 20BR cartridge and Reese Outdoors Products.  Thanks for listening! Music by The Dirt Road Scholars  Facebook - https://www.facebook.com/ffppodcast/ Instagram - https://www.instagram.com/firstfocalplane/

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.06.03.132522v1?rss=1 Authors: Pocuca, N., Young, J. W., MacQueen, D. A., Letendre, S., Heaton, R. K., Geyer, M. A., Perry, W., Grant, I., Minassian, A., Translational Methamphetamine AIDS Research Center (TMARC) Abstract: Background: Human immunodeficiency virus (HIV)-associated neurocognitive disorders persist in the era of antiretroviral therapy (ART). One factor that is elevated among persons with HIV (PWH) and independently associated with neurocognitive impairment is methamphetamine dependence (METH+). Such dependence may further increase cognitive impairment among PWH, by delaying HIV diagnosis (and thus, ART initiation), which has been posited to account for persistent cognitive impairment among PWH, despite subsequent treatment-related viral load suppression (VLS;

每天清晨，在慕尼黑郊外，总有一位德国老人在附近森林里安静地行走。已经77岁高龄的他身材高大、满头白发，但精神矍铄。他就是奥贝尔格（Jürgen Oberg），西门子北京代表处的第一任首席代表。30多年前，正是在他的带领下，西门子从一个只有数名员工的小小代表处开始，通过一点一滴的努力，获得客户与合作伙伴的认可。现年77岁的奥贝尔格。在西门子老员工连瑞庭眼里，奥贝尔格是个“中国通”，懂中国国情，还爱吃中餐。最厉害的是他记忆力过人，凡是见过的人，下次再见面一定叫得出名字。扎根中国奥贝尔格首次踏上中国的土地是在1984年3月。至今他还记得当时北京的街道上很难看到小轿车，而长安街更是自行车的天下。几个月以后，他的太太和两个儿子（10岁和6岁）也跟着搬到北京。有意思的是，时常有中国人不相信两个男孩的金色头发是真的。这也给孩子们带来了小小的烦恼。1984年7月1日，43岁的奥贝尔格到设在民族饭店的西门子北京代表处上任。在这之前，他曾多年负责西门子在前苏联的业务，熟悉社会主义国家的情况。他深知自己面对的是一个积贫积弱但潜力无限的东方大国，前路任重而道远。上世纪八十年代，奥贝尔格与西门子北京代表处的同事们在一起。在中国改革开放历史上，1984年是个特别的年份。在这一年，一大批民营企业诞生，创业潮如星火燎原席卷全国。此时的西门子在中国同样处于创业起步阶段。当时的北京代表处刚刚成立不到两年，主要业务由香港捷成洋行代理。自1955年起，捷成洋行便在中国市场分销西门子的产品，主要是医疗器械。奥贝尔格认为这样的力度远远不够。他曾经在一次内部会议上明确表示：“西门子这么大的跨国公司，在中国这么大的国家，我们只有发展自主业务才能充分代表自己的利益，才能全面地和中国合作，也才能更贴近中国客户！”西门子在1985年12月31日正式结束了与捷成洋行的协议，由此驶入在华发展的快车道。坚持原则在许多人眼里，奥贝尔格为人有自己的原则。他坦率、正直，甚至有些“不近人情”。无论面对中国人还是外国人，他都坦诚以对。当时在北京代表处负责政府事务的刘长华讲述了一个让他难以忘怀的故事。1984年开工建设的秦皇岛港煤码头三期工程是中国“七五规划”的重点项目。这个项目由德国PWH公司负责总包建设，由西门子提供PLC控制设备和计算机管理系统。没想到的是PWH公司在项目完工之前就突然宣布破产。这给中方和西门子都出了个大难题。按照规定，PWH公司的破产管理委员会不允许西门子继续供货。即使西门子供货，PWH一旦付款，也会被破产管理委员会拿到，用于补偿失业工人。但是项目重大，中方需要维持工程建设，因此希望西门子继续提供设备。连当时主管部门领导也找到奥贝尔格，提出：“你们不用担心拿不到货款，我们一定会补偿你们！”1987年，奥贝尔格在北京日坛公园。当时为两人担任翻译的刘长华紧张得直冒汗，而奥贝尔格却异常冷静。他没有过多犹豫便坦诚相告：“对不起，我们没有总部的授权，确实无法供货”。在回去的路上，他对刘长华说：“刘，我看得出你很紧张。但是你要记住一点，我们不能答应我们做不到的事情。今天我可以撒谎，这样双方和和气气。但是三天之后，对方一旦知道实情就永远不会再见我们了。”尽管这件事的结果并非皆大欢喜，但正是这样的坦诚和坚持原则才使西门子在改革开放初期就赢得了中国客户与合作伙伴的尊重。中德合作的“推手”奥贝尔格身上有着德国人特有的严谨和认真，但对待同事却十分温暖。而老员工刘长华却对奥贝尔格的守时印象深刻。打个比方，即使是一年前确认参加的活动，中间没有任何电话或电传联系，但是到时间了他一定会分秒不差地准时出现。奥贝尔格极为看好中国市场的前景，希望与中方推动技术合作，共建合资企业，让西门子的业务茁壮成长。那段时间，他最经常思考的问题就是如何让客户与合作伙伴们坚信一个事实，那就是西门子并不会对德国、中国、巴西或任何国家差别对待，而是以同样高标准的西门子质量服务全球近200个国家。在中国领导人面前，他谦逊有礼、不卑不亢。用刘长华的话说，“他从来没有失掉作为西门子首席代表的尊严”。1985年10月29日是奥贝尔格终生难忘的日子。这一天在人民大会堂，西门子和中国政府签署了全面合作的备忘录。西门子成为了第一家应邀与中国进行如此深入合作的外国企业。为了当天的签约，他和同事们已经付出了长达半年的努力。当双方代表在厚厚的备忘录上签字盖章时，站在最后一排的奥贝尔格面露微笑。他激动地鼓掌，内心无比骄傲。尽管明天仍然充满未知，但他深信一点，这次合作将为公司在华业务的蓬勃兴盛打下坚实基础。1985年10月29日，西门子和中国政府在人民大会堂签署全面合作备忘录。在1987财年，西门子在中国实现了近3亿德国马克的销售额。到1988年，公司已经在中国设立了四个办事处，拥有约150名员工。心系中国的德国老人奥贝尔格唯一的爱好就是足球，但是他从来不踢，因为实在是抽不出时间。在北京工作时，他总是让秘书帮忙记录德国国家队和德甲联赛比赛的结果，然后再汇报给他。在1989年底回到西门子德国工作以后，他每年也出差到中国两三次。他见证了深圳从一个小渔村成长为备受瞩目的科技创新重镇，也亲历了浦东从一片荒地和农田转变为繁华的金融和贸易中心。西门子占据了他生活的全部，他的太太一度还很担心，2006年退休以后不再接触西门子了，那他该怎么办？！好在老人很快适应了新的生活。现在他经常跑步健身，参加学术活动，定期上历史课，也偶尔参加西门子退休高管的聚会。即使退居二线，他仍然牵挂着西门子，也关注着中国的改革开放进程。“只要中国继续保持对内对外的和平与稳定，我相信她将拥有更加美好的未来。作为中国的老朋友，我衷心希望这样的和平与稳定能够长长久久。”奥贝尔格说道。

With us on this Episode of the Global Cable is Former President of Mexico and Distinguished Global Leader-In-Residence Felipe Calderón to discuss important issues facing the world, the US-Mexico relationship, climate change and his time with us at the University of Pennsylvania, with Professor William Burke-White, the inaugural direct of Perry World House.  Perry World House Distinguished Global Leader-In-Residence Felipe Calderón served as President of Mexico from 2006 to 2012. Prior to his presidency, Calderón was Secretary of Energy (and in that capacity Chairman of the Board of Pemex and CFE) and director of BANOBRAS (Public  Works Bank). He was also a Congressman, leader of the National Action Party (PAN) in the Congress, and Secretary General and National President of PAN. 0:28 - Introduction 1:10 - President Calderón's visit to PWH and Philadelphia 3:12 - The U.S. - Mexico Relationship and Trade 8:30 - Immigration Issues 15:30 - The Economic Case for Tackling Climate Change 27:00 - How to Embark on a Career in International Affairs 29:00 - Outro     Music and Produced by Tre Hester